For years, Napo Pharmaceuticals Inc. has been blaming its troubles on Salix Pharmaceuticals Ltd., a business partner that allegedly never delivered on a promise to promote a potentially lucrative Napo drug. On Tuesday, a state court jury in Manhattan told Napo to pin the blame elsewhere, handing a big win to Salix and its lawyers at Covington & Burling.
According to a Salix press release, jurors returned a verdict that the company didn’t breach a promise to use reasonable efforts to commercialize the Napo drug Fulyzaq (crofelemer), which is used to treat HIV-related diarrhea. Napo, which was represented by a Boies, Schiller & Flexner team led by William Ohlemeyer, put damages at about $260 million in damages in an expert report.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
